Scholarlink

<p>This study examined if the announcement of the EU AI Act was associated with changes in market access and the pace of innovation for AI-enabled healthcare devices within the European Union. The analysis compared pre- and post-announcement periods to determine whether challenges and criticisms identified in prior research corresponded with significant changes in market access or pace of innovation. Specifically, the study investigated market access by analyzing the number of regulatory approvals for AI-enabled medical devices and the rate of innovation, measured by the number of new patent filings for AI-enabled healthcare products. The analysis also considered the volume of venture capital funding directed toward AI healthcare startups and small and medium-sized enterprises in the EU. Data were collected from publicly available sources, including the FDA, OECD Policy Observatory, Health AI Register, and WIPO Patentscope, over a 6-year period. The findings reveal no sustained, statistically significant change in the post-intervention period across all data sources except the OECD data, where descriptive statistics indicated a difference in mean values between EU and non-EU countries. Overall, the study found that the announcement of the EU AI Act did not lead to significant changes in the number of approved devices in the EU, contrary to what previous research had suggested. These results provide policymakers, economic operators in the AI medical device/healthcare&#xa0;sector, and global regulators with insights into the relationship between AI-specific regulations and economic outcomes.</p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

Diagnosing the impact of the EU AI Act on market access and pace of innovation of AI-enabled healthcare devices in the EU

  • 期刊论文

  • 出版模式：

    开放获取

  • 发表日期：

    2026年2月10日

查看全文
  • Edmund B. Graham,
  • Elif Nur Akcan

摘要

This study examined if the announcement of the EU AI Act was associated with changes in market access and the pace of innovation for AI-enabled healthcare devices within the European Union. The analysis compared pre- and post-announcement periods to determine whether challenges and criticisms identified in prior research corresponded with significant changes in market access or pace of innovation. Specifically, the study investigated market access by analyzing the number of regulatory approvals for AI-enabled medical devices and the rate of innovation, measured by the number of new patent filings for AI-enabled healthcare products. The analysis also considered the volume of venture capital funding directed toward AI healthcare startups and small and medium-sized enterprises in the EU. Data were collected from publicly available sources, including the FDA, OECD Policy Observatory, Health AI Register, and WIPO Patentscope, over a 6-year period. The findings reveal no sustained, statistically significant change in the post-intervention period across all data sources except the OECD data, where descriptive statistics indicated a difference in mean values between EU and non-EU countries. Overall, the study found that the announcement of the EU AI Act did not lead to significant changes in the number of approved devices in the EU, contrary to what previous research had suggested. These results provide policymakers, economic operators in the AI medical device/healthcare sector, and global regulators with insights into the relationship between AI-specific regulations and economic outcomes.